Skip to main content
Premium Trial:

Request an Annual Quote

Syapse Closes $30M Series D Round

CHICAGO (GenomeWeb) – Syapse, a maker of software to support precision oncology care, has raised $30 million in a Series D round of venture capital from a variety of investors.

Previous investors that participated in the new round include Ascension Ventures, GE Ventures, Intermountain Healthcare Innovation Fund, Safeguard Scientifics, and Social Capital. Also investing this time are Amgen Ventures, Medidata Solutions, Merck Global Health Innovation Fund, and Roche Venture Fund.

San Francisco-based Syapse said it would use the cash infusion to step up sales and support for more hospitals, including community health systems. The company said this would help more eligible patients find and participate in relevant clinical trials.

"Targeted therapeutics and precision diagnostics have been shown to save lives and lower the cost of care, but without tools like Syapse, they've been inaccessible to the community oncologists that represent 70 percent of patient care," John Kuelper, investment director at Ascension Ventures, said in a statement. "Syapse empowers physicians to collaborate with each other and the broader medical ecosystem, ensuring that these breakthrough technologies are available to the patients who need them."

Syapse last announced a fundraise in early 2016, when it closed on a $25 million Series C round.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more